دورية أكاديمية
أعرض في EDS

Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells.

التفاصيل البيبلوغرافية
العنوان: Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells.
المؤلفون: Collins HM; Gene Regulation Group, Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, University Park, NG7 2RD, Nottingham. United Kingdom., Abdelghany MK, Messmer M, Yue B, Deeves SE, Kindle KB, Mantelingu K, Aslam A, Winkler GS, Kundu TK, Heery DM
المصدر: BMC cancer [BMC Cancer] 2013 Jan 29; Vol. 13, pp. 37. Date of Electronic Publication: 2013 Jan 29.
نوع المنشور: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Breast Neoplasms/*metabolism , Curcumin/*pharmacology , Histones/*metabolism , Protein Processing, Post-Translational/*drug effects , Terpenes/*pharmacology , Tumor Suppressor Protein p53/*metabolism, Acetylation ; Blotting, Western ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; CREB-Binding Protein/metabolism ; Cell Cycle/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; DNA Damage ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/pharmacology ; Female ; Flow Cytometry ; Histone Acetyltransferases/antagonists & inhibitors ; Histone Acetyltransferases/metabolism ; Histone-Lysine N-Methyltransferase/antagonists & inhibitors ; Histone-Lysine N-Methyltransferase/genetics ; Histone-Lysine N-Methyltransferase/metabolism ; Humans ; Immunohistochemistry ; Lysine Acetyltransferase 5 ; MCF-7 Cells ; Methylation ; Polymerase Chain Reaction ; RNA Interference ; Time Factors ; Transfection
مستخلص: Background: Post-translational modifications (PTMs) of histones and other proteins are perturbed in tumours. For example, reduced levels of acetylated H4K16 and trimethylated H4K20 are associated with high tumour grade and poor survival in breast cancer. Drug-like molecules that can reprogram selected histone PTMs in tumour cells are therefore of interest as potential cancer chemopreventive agents. In this study we assessed the effects of the phytocompounds garcinol and curcumin on histone and p53 modification in cancer cells, focussing on the breast tumour cell line MCF7.
Methods: Cell viability/proliferation assays, cell cycle analysis by flow cytometry, immunodetection of specific histone and p53 acetylation marks, western blotting, siRNA and RT-qPCR.
Results: Although treatment with curcumin, garcinol or the garcinol derivative LTK-14 hampered MCF7 cell proliferation, differential effects of these compounds on histone modifications were observed. Garcinol treatment resulted in a strong reduction in H3K18 acetylation, which is required for S phase progression. Similar effects of garcinol on H3K18 acetylation were observed in the osteosarcoma cells lines U2OS and SaOS2. In contrast, global levels of acetylated H4K16 and trimethylated H4K20 in MCF7 cells were elevated after garcinol treatment. This was accompanied by upregulation of DNA damage signalling markers such as γH2A.X, H3K56Ac, p53 and TIP60. In contrast, exposure of MCF7 cells to curcumin resulted in increased global levels of acetylated H3K18 and H4K16, and was less effective in inducing DNA damage markers. In addition to its effects on histone modifications, garcinol was found to block CBP/p300-mediated acetylation of the C-terminal activation domain of p53, but resulted in enhanced acetylation of p53K120, and accumulation of p53 in the cytoplasmic compartment. Finally, we show that the elevation of H4K20Me3 levels by garcinol correlated with increased expression of SUV420H2, and was prevented by siRNA targeting of SUV420H2.
Conclusion: In summary, although garcinol and curcumin can both inhibit histone acetyltransferase activities, our results show that these compounds have differential effects on cancer cells in culture. Garcinol treatment alters expression of chromatin modifying enzymes in MCF7 cells, resulting in reprogramming of key histone and p53 PTMs and growth arrest, underscoring its potential as a cancer chemopreventive agent.
References: EMBO J. 2009 Jul 8;28(13):1878-89. (PMID: 19407812)
Nat Genet. 2005 Apr;37(4):391-400. (PMID: 15765097)
EMBO J. 2011 Jan 19;30(2):249-62. (PMID: 21131905)
Mol Cell Biol. 2005 Nov;25(21):9175-88. (PMID: 16227571)
Science. 2008 Aug 22;321(5892):1086-8. (PMID: 18719284)
PLoS One. 2010 Dec 29;5(12):e14447. (PMID: 21206904)
J Biol Chem. 2009 Jul 24;284(30):20197-205. (PMID: 19494119)
Chem Biol. 2007 Jun;14(6):645-57. (PMID: 17584612)
Mol Cell Biol. 2010 Jul;30(14):3582-95. (PMID: 20479123)
Science. 2004 Dec 17;306(5704):2084-7. (PMID: 15528408)
Cell. 2007 Feb 23;128(4):693-705. (PMID: 17320507)
Science. 2001 Aug 10;293(5532):1074-80. (PMID: 11498575)
Science. 2008 Aug 22;321(5892):1084-5. (PMID: 18719283)
Br J Cancer. 2009 May 5;100(9):1425-33. (PMID: 19401701)
Mol Cell. 2006 Dec 28;24(6):827-39. (PMID: 17189186)
J Clin Oncol. 2007 Oct 1;25(28):4358-64. (PMID: 17906200)
Biochem Soc Symp. 2006;(73):23-39. (PMID: 16626284)
Ann Surg Oncol. 2008 Jul;15(7):1968-76. (PMID: 18470569)
Mol Cancer Ther. 2007 Apr;6(4):1239-48. (PMID: 17406032)
Cancer Lett. 2005 Apr 18;221(1):29-39. (PMID: 15797624)
Mol Cell Biol. 2008 Jan;28(1):468-86. (PMID: 17967882)
J Cell Biochem. 2010 Apr 15;109(6):1134-41. (PMID: 20108249)
Drug Discov Today. 2007 Jan;12(1-2):88-99. (PMID: 17198977)
Trends Cell Biol. 2009 May;19(5):207-17. (PMID: 19342239)
Cancer Res. 2009 May 1;69(9):3802-9. (PMID: 19366799)
J Biol Chem. 2004 Dec 3;279(49):51163-71. (PMID: 15383533)
J Agric Food Chem. 2000 Feb;48(2):180-5. (PMID: 10691613)
Nat Struct Mol Biol. 2008 Oct;15(10):1122-4. (PMID: 18794842)
Mol Cell Biol. 2005 Aug;25(15):6798-810. (PMID: 16024812)
Nat Struct Mol Biol. 2007 Nov;14(11):1025-1040. (PMID: 17984965)
Mol Cell Biol. 2011 Apr;31(8):1594-609. (PMID: 21321083)
Mol Cell. 2006 Dec 28;24(6):841-51. (PMID: 17189187)
Cell. 1997 Aug 22;90(4):595-606. (PMID: 9288740)
Mol Cell Biol. 2007 Oct;27(20):7028-40. (PMID: 17709392)
J Biol Chem. 2004 Aug 6;279(32):33716-26. (PMID: 15155757)
Cell. 2004 Nov 24;119(5):603-14. (PMID: 15550243)
J Biol Chem. 2008 May 23;283(21):14497-505. (PMID: 18362141)
J Med Chem. 2009 Jan 22;52(2):267-77. (PMID: 19086895)
Science. 2006 Feb 10;311(5762):844-7. (PMID: 16469925)
EMBO J. 2010 Jan 6;29(1):158-70. (PMID: 19875981)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
Mol Biol Cell. 2009 Sep;20(17):3840-50. (PMID: 19605561)
Oncogene. 2007 Aug 13;26(37):5528-40. (PMID: 17694092)
Int J Mol Med. 2011 Sep;28(3):429-35. (PMID: 21519785)
Nature. 2005 Jun 30;435(7046):1262-6. (PMID: 15988529)
Nat Protoc. 2007;2(6):1445-57. (PMID: 17545981)
معلومات مُعتمدة: 07-0494 United Kingdom AICR_ Worldwide Cancer Research; 11643 United Kingdom CRUK_ Cancer Research UK; United Kingdom MRC_ Medical Research Council; United Kingdom BB_ Biotechnology and Biological Sciences Research Council
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Enzyme Inhibitors)
0 (H2AX protein, human)
0 (Histones)
0 (TP53 protein, human)
0 (Terpenes)
0 (Tumor Suppressor Protein p53)
EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
EC 2.1.1.43 (KMT5C protein, human)
EC 2.3.1.48 (CREB-Binding Protein)
EC 2.3.1.48 (CREBBP protein, human)
EC 2.3.1.48 (Histone Acetyltransferases)
EC 2.3.1.48 (KAT5 protein, human)
EC 2.3.1.48 (Lysine Acetyltransferase 5)
IT942ZTH98 (Curcumin)
TR1VR1V71B (garcinol)
تواريخ الأحداث: Date Created: 20130130 Date Completed: 20130614 Latest Revision: 20211021
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC3583671
DOI: 10.1186/1471-2407-13-37
PMID: 23356739
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/1471-2407-13-37